In this multicenter retrospective cohort and review of the literature, we investigated whether the use of CCR5 antagonists influences the outcome of iatrogenic iPML/PML-IRIS related to immunosuppressive agents for the treatment of chronic inflammatory diseases. This evidence concerns the gene CCR5 and progressive multifocal leukoencephalopathy.